Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM.

Int J Cancer. 2009 May 15;124(10):2416-29. doi: 10.1002/ijc.24202. Review.

2.

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P.

Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8.

3.

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study.

Rowlands MA, Holly JM, Gunnell D, Gilbert R, Donovan J, Lane JA, Marsden G, Collin SM, Hamdy F, Neal DE, Martin RM.

Cancer Causes Control. 2010 Nov;21(11):1829-42. doi: 10.1007/s10552-010-9610-x. Epub 2010 Jul 23.

PMID:
20652394
4.

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM.

Cancer Res. 2012 Jan 15;72(2):503-15. doi: 10.1158/0008-5472.CAN-11-1601. Epub 2011 Nov 21.

5.

Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.

Bonilla C, Lewis SJ, Rowlands MA, Gaunt TR, Davey Smith G, Gunnell D, Palmer T, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Martin RM, Holly JM.

Int J Cancer. 2016 Oct 1;139(7):1520-33. doi: 10.1002/ijc.30206. Epub 2016 Jun 23.

6.

Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis.

Harrison S, Lennon R, Holly J, Higgins JPT, Gardner M, Perks C, Gaunt T, Tan V, Borwick C, Emmet P, Jeffreys M, Northstone K, Rinaldi S, Thomas S, Turner SD, Pease A, Vilenchick V, Martin RM, Lewis SJ.

Cancer Causes Control. 2017 Jun;28(6):497-528. doi: 10.1007/s10552-017-0883-1. Epub 2017 Mar 30. Review.

7.

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study.

Rowlands MA, Tilling K, Holly JM, Metcalfe C, Gunnell D, Lane A, Davis M, Donovan J, Hamdy F, Neal DE, Martin RM.

Cancer Causes Control. 2013 Jan;24(1):39-45. doi: 10.1007/s10552-012-0087-7. Epub 2012 Oct 21.

PMID:
23085814
8.

Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7.

9.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

PMID:
11106682
10.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JAMJL, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak M, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE.

Cancer Res. 2016 Apr 15;76(8):2288-2300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

11.

The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery.

Cotterill AM, Mendel P, Holly JM, Timmins AG, Camacho-Hübner C, Hughes SC, Ross RM, Blum WF, Langford RM.

Clin Endocrinol (Oxf). 1996 Jan;44(1):91-101.

PMID:
8706300
12.

Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells.

Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY.

Eur J Cancer. 2001 Nov;37(17):2257-63.

PMID:
11677116
13.

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer.

Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM.

Cancer Causes Control. 2012 Feb;23(2):347-54. doi: 10.1007/s10552-011-9883-8. Epub 2011 Dec 20.

PMID:
22183619
14.

Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.

Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP.

Br J Cancer. 1996 Oct;74(8):1242-7.

15.

Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.

Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1137-41.

16.

Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.

Grønbaek H, Flyvbjerg A, Mellemkjaer L, Tjønneland A, Christensen J, Sørensen HT, Overvad K.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1759-64.

17.

Insulin-like growth factor-I and binding protein-3 and risk of cancer.

Giovannucci E.

Horm Res. 1999;51 Suppl 3:34-41. Review.

PMID:
10592442
18.

Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis.

Chi F, Wu R, Zeng YC, Xing R, Liu Y.

Mol Biol Rep. 2013 May;40(5):3583-90. doi: 10.1007/s11033-012-2432-z. Epub 2012 Dec 27. Review.

PMID:
23269623
20.

Characterization of insulin-like growth factors and their binding proteins in peritoneal dialysate.

Kale AS, Liu F, Hintz RL, Baker BK, Brewer ED, Lee PD, Durham SK, Powell DR.

Pediatr Nephrol. 1996 Aug;10(4):467-73.

PMID:
8865245

Supplemental Content

Support Center